PRP Kit Selection for Orthopedic and Sports Medicine Practices: A Chemist's Guide to Closed-System Integrity, Anticoagulant Selection, and Centrifuge Parameters

Why PRP Kit Selection Determines Clinical Outcomes

Platelet-rich plasma has become a foundational orthobiologic across orthopedic and sports medicine practice, with growing evidence of clinical efficacy in knee osteoarthritis, tendinopathy, and post-surgical recovery protocols. A 2025 narrative review synthesizing 40 high-quality studies published between 2013 and March 2025 found that PRP injections, particularly leukocyte-poor PRP, demonstrate superior pain relief and functional improvement compared to hyaluronic acid and corticosteroids in patients with mild to moderate knee osteoarthritis at Kellgren-Lawrence grades I to III (Filardo et al., Journal of Clinical Medicine, 2025. https://doi.org/10.3390/jcm14113983).

What is less discussed in clinical practice is that the term PRP refers to a category of preparations rather than a single standardized product. A 2024 systematic review and network meta-analysis covering randomized controlled trials through September 2024 documented substantial variability in PRP preparation methods, platelet concentrations, and dosing regimens across the published literature, with the optimal dosage strategy still under active investigation (Babaei et al., Journal of Orthopaedic Surgery and Research, 2025. https://doi.org/10.1186/s13018-025-05650-1). The same volume of whole blood processed through different kits can yield preparations that differ by orders of magnitude in platelet concentration, leukocyte content, and growth factor release profile.

For orthopedic practices that prescribe PRP for injection rather than topical application, the analytical chemistry of the kit determines what the patient actually receives. This article examines the chemistry of closed-system PRP preparation, the role of anticoagulant selection in preserving platelet bioactivity, the centrifuge parameters that drive platelet recovery, and the documentation standards that distinguish a well-characterized clinical kit from a commodity product.

Closed-System Integrity: Why It Matters for Injectable PRP

A closed-system PRP kit is one in which the blood collection, separation, and final draw-up steps occur within a single integrated tube system without exposing the preparation to ambient air. The closed system is particularly important for orthopedic injection protocols because the final preparation will be administered intra-articularly or peri-tendinously, where contamination risk is clinically significant.

The core components of a closed-system kit are the collection tube with anticoagulant, a separator gel that creates a physical barrier between cellular fractions during centrifugation, and a draw-up port that allows the clinician to extract the platelet-rich layer without breaking the tube seal. The Spanish Agency for Medications and Health Products (AEMPS) framework references closed-system kit design as a baseline requirement for safe, consistent, high-quality PRP preparation in clinical practice (Fidia RICHPLAT ORTHO Instructions for Use, AEMPS regulatory framework. https://www.aemps.gob.es).

Open-system kits, in which blood is transferred between multiple tubes during processing, introduce additional risk vectors: exposure to ambient air can affect platelet activation kinetics, multiple tube transfers increase the probability of contamination, and operator technique becomes a larger source of preparation-to-preparation variance. For orthopedic injection protocols, the closed-system architecture is the appropriate baseline.

Anticoagulant Selection: ACD-A and Its Role in Platelet Preservation

The anticoagulant used in the collection tube is a chemistry decision with direct clinical consequences. The three commonly used anticoagulants in PRP collection tubes are Acid Citrate Dextrose Solution A (ACD-A), sodium citrate, and heparin, with ACD-A established as the analytical preference for orthopedic and sports medicine PRP applications.

ACD-A is a balanced solution containing citric acid, sodium citrate, and dextrose. The citrate component chelates calcium ions, preventing the calcium-dependent activation of the coagulation cascade. The dextrose component provides metabolic substrate that maintains platelet viability during the processing window. The combined effect is preservation of platelet integrity through centrifugation and final preparation, with platelets remaining inactive until the clinician initiates activation through calcium chloride addition or through the natural exposure to subendothelial collagen at the injection site.

Sodium citrate-only preparations achieve anticoagulation but lack the metabolic substrate of ACD-A, which can affect platelet viability over the processing window. Heparin-based anticoagulants are not recommended for PRP because heparin can interfere with platelet aggregation and growth factor release, reducing the bioactivity of the final preparation.

The ACD-A approach has additional clinical relevance: when paired with a separator gel and proper centrifugation, it produces PRP with higher concentrations of intact, non-prematurely-activated growth factors compared to alternative anticoagulants. This preservation of platelet bioactivity translates into more reliable release of platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF) at the injection site, which are the molecular drivers of the regenerative response.

Gel Separator Chemistry and Its Function in Platelet Recovery

The separator gel in a PRP tube is a polyester or silica-based material with a specific gravity calibrated to position itself between the red blood cell layer and the plasma layer during centrifugation. The gel forms a stable physical barrier after centrifugation, allowing the clinician to draw off the platelet-rich plasma fraction without disturbing the red blood cell layer below.

The chemistry of the gel matters for several reasons. The gel must remain inert with respect to platelet biology, meaning it should not activate platelets prematurely, should not absorb growth factors, and should not introduce contaminants into the preparation. Polyester and silica-based gels meeting medical-grade specifications are designed for this inertness, and the validated specific gravity of the gel determines how cleanly the plasma fraction separates from the cellular fractions.

A poorly designed gel separator can result in red blood cell contamination of the plasma layer, which introduces hemoglobin and free heme into the preparation. Hemoglobin and free heme have been associated with pro-inflammatory effects at injection sites, which can compromise the regenerative intent of the protocol. Practices evaluating PRP kit options should confirm the gel separator material specification with the supplier and request documentation of the validated centrifugation parameters that produce the cleanest separation.

Centrifugation Parameters: The Often-Overlooked Variable

The centrifugation protocol used to prepare PRP is a primary determinant of the final platelet concentration, leukocyte content, and growth factor release profile. The relevant parameters are relative centrifugal force (RCF, expressed in g), spin duration, and whether the protocol is single-spin or double-spin.

Single-spin protocols are commonly used in clinical practice because they are faster and produce moderate platelet concentrations suitable for many indications. A typical single-spin protocol runs at approximately 1500 to 1900 g for 5 to 10 minutes depending on the kit and centrifuge specification. The Fidia RICHPLAT ORTHO closed-system kit is documented to produce 8 mL of concentrated PRP at 2.3 times final concentration above baseline from an 18 mL whole blood draw using a one-touch centrifugation protocol (Fidia RICHPLAT ORTHO PRP System, data on file. https://www.fidiaprp.com/).

Double-spin protocols use two sequential centrifugation steps, with the first spin separating cellular fractions broadly and the second spin further concentrating the platelets in the plasma layer. Double-spin protocols typically produce higher platelet concentrations but require longer total processing time and introduce additional handling steps.

The clinical relevance of dose has been examined in the recent literature. The 2024 network meta-analysis comparing single, double, and triple PRP injection protocols found that the optimal dosage strategy depends on the indication, the preparation platelet concentration, and the patient population, with the data supporting that higher absolute platelet doses are associated with superior pain reduction in knee osteoarthritis at moderate Kellgren-Lawrence grades (Babaei et al., Journal of Orthopaedic Surgery and Research, 2025. https://doi.org/10.1186/s13018-025-05650-1).

Leukocyte Content: Leukocyte-Poor versus Leukocyte-Rich PRP

A distinction that has become increasingly important in the orthopedic literature is the difference between leukocyte-poor PRP (LP-PRP) and leukocyte-rich PRP (LR-PRP). LP-PRP preparations contain a reduced concentration of white blood cells relative to whole blood baseline, while LR-PRP preparations contain elevated concentrations.

The clinical evidence for orthopedic indications has tilted toward LP-PRP in recent meta-analyses. The 2025 narrative review of 40 high-quality studies concluded that leukocyte-poor PRP demonstrated superior outcomes in knee osteoarthritis compared to leukocyte-rich preparations, particularly in mild to moderate disease (Filardo et al., Journal of Clinical Medicine, 2025. https://doi.org/10.3390/jcm14113983). The mechanistic rationale is that elevated leukocyte concentrations introduce pro-inflammatory cytokines including IL-1β and TNF-α at the injection site, which can amplify rather than resolve joint inflammation in the chronic OA setting.

Kit selection determines whether a practice will routinely produce LP-PRP or LR-PRP. The buffy coat layer in the centrifuged tube contains the majority of leukocytes, and the technique used to draw off the plasma layer determines the leukocyte content of the final preparation. Closed-system kits with validated draw-up protocols produce more reproducible leukocyte content than open-system kits where operator technique introduces session-to-session variance.

What Practices Should Evaluate in a PRP Kit Supplier

For orthopedic and sports medicine practices building or transitioning a PRP supply chain, the following analytical documentation standards should be applied to any prospective kit supplier.

503A Research Peptides for Orthopedic and Sports Medicine Practices

Beyond PRP, the 503A compounding pharmacy formulary includes peptides that are increasingly referenced in sports medicine and orthopedic recovery protocols for research and patient-specific compounded use. The regulatory status of several of these compounds is in active flux as of April 2026, and practices must verify current compound availability with their pharmacy partner before prescribing.

Sermorelin is a 29-amino acid synthetic GHRH analog with an established safety profile and is currently available through 503A compounding for patient-specific prescriptions. Sermorelin stimulates pituitary growth hormone release through the GHRH receptor, producing physiological pulsatile GH secretion that has been referenced in age-related recovery and tissue repair protocols.

BPC-157 has demonstrated tissue repair properties in published preclinical research. As of 2025, BPC-157 was placed in Category 2 of the FDA interim 503A Bulks List, which prohibits 503A compounding pending PCAC review (Frier Levitt regulatory analysis, 2025. https://www.frierlevitt.com/articles/regulatory-status-of-peptide-compounding-in-2025/). Practices should confirm current compounding eligibility with their pharmacy partner before prescribing.

TB-500 (thymosin beta-4 fragment) has been referenced in the regenerative literature for tissue repair indications. Like BPC-157, the regulatory status for 503A compounding is currently restricted pending PCAC review. Verify current eligibility before prescribing.

Tesamorelin is an FDA-approved GHRH analog (Egrifta, approved for HIV-associated lipodystrophy) and is available through compounding partners with a more established regulatory footing than non-approved GHRH analogs.

The compounded peptide landscape in 2026 requires close attention to current regulatory status. The Frier Levitt regulatory analysis confirms that under the 2019 Biologics Price Competition and Innovation Act framework, 503A pharmacies may compound peptides only when the compound is FDA-approved, has GRAS status, has a USP monograph, or appears on Category 1 of the 503A Bulks List, with most other peptides currently restricted (Frier Levitt, 2025. https://www.frierlevitt.com/articles/regulatory-status-of-peptide-compounding-in-2025/).

The ExaVeyra Catalog for Orthopedic and Sports Medicine Practices

ExaVeyra Sciences supplies the full procedural stack for NPI-verified orthopedic and sports medicine practices.

NPI-verified wholesale access required for all products. Apply at exaveyra.com/apply.